quienes no deberian tomar el tirzepatide SOCHOB Tirzepatide: A New Hope for

primary-cta What is Pancreatitis

Esta combinacin de retraso del vaciado gstrico y aumento de la sensacin de saciedad hace de la semaglutida una herramienta til y eficaz para el control del peso y la obesidad

While reduced appetite is a therapeutic benefit that supports weight loss, it also presents a nutritional challenge

Who Should Consider GLP-1 Therapy FDA indications for weight loss require: BMI 30 (obesity), or BMI 27 (overweight) with at least one weight-related condition hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or similar These thresholds set eligibility, but they don't answer the more important question: who benefits most